The global automated and closed cell therapy processing systems market size was estimated at USD 1.67 billion in 2025 and is projected to reach USD 7.44 billion by 2033, growing at a CAGR of 20.73% from 2026 to 2033. This strong growth is primarily driven by the increasing adoption of regenerative medicine and cell-based therapies worldwide. In parallel, the numerous operational and technical advantages offered by automated technologies—such as improved consistency, enhanced efficiency, reduced human error, and better process control in therapy development—are significantly contributing to market expansion.

Furthermore, the rising integration of advanced software platforms and digital tools into therapy development and manufacturing workflows is expected to further accelerate market growth. Biopharmaceutical and biotechnology manufacturers are increasingly investing in the development of cellular therapy products, supported by multiple rounds of series funding, which is creating substantial growth opportunities across the industry. In addition, the growing demand for scalable, safe, and contamination-free cell therapy manufacturing solutions is strengthening market momentum. This trend is further supported by technological innovations such as the adoption of animal origin-free formulations, which enhance product safety, regulatory compliance, and overall manufacturing reliability, thereby driving the continued expansion of the market.

Key Market Trends & Insights:

• The North America automated and closed cell therapy processing systems market held the largest share of 50.09% of the global market in 2025, reflecting the region’s strong presence in advanced healthcare infrastructure, biotechnology research, and the early adoption of automated manufacturing technologies. This dominant position is supported by significant investments in regenerative medicine and well-established regulatory frameworks that encourage innovation and commercialization.

• The automated and closed cell therapy processing systems industry in the U.S. is expected to grow significantly over the forecast period, driven by increasing research activities, rising clinical trials for advanced therapies, and strong funding from both public and private organizations. The presence of key market players and leading academic institutions further supports sustained industry expansion in the country.

• By workflow, the separation services segment held the largest market share of 31.72% in 2025, primarily due to its critical role in isolating and purifying target cells during cell therapy manufacturing. The growing need for high-purity cell populations and efficient processing techniques has strengthened the importance of this workflow step within the overall production process.

• Based on type, the non-stem cell therapy segment held the largest market share in 2025, supported by the increasing development and commercialization of therapies based on immune cells and other differentiated cell types. This segment’s growth is linked to its broad clinical applications and relatively faster regulatory pathways in certain therapeutic areas.

• By scale, the pre-commercial/R&D scale segment held the largest market share in 2025, as a significant portion of cell therapy activities remains focused on research, clinical development, and early-stage manufacturing. The strong emphasis on innovation, process optimization, and clinical validation at this scale continues to drive its leading position in the market.

Order a free sample PDF of the Automated And Closed Cell Therapy Processing Systems Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2025 Market Size: USD 1.67 Billion

• 2033 Projected Market Size: USD 7.44 Billion

• CAGR (2026-2033): 20.73%

• North America: Largest market in 2025

• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

The market is highly competitive and characterized by the strong presence of both well-established bioprocessing equipment manufacturers and specialized automation technology providers. Leading companies such as Miltenyi Biotec, Sartorius Stedim Biotech, Thermo Fisher Scientific, Lonza, and Danaher command significant market shares by leveraging their broad product portfolios, well-developed global distribution networks, and long-standing strategic partnerships. Their continued focus on research and development, along with consistent product innovation, enables them to maintain strong competitive positions in a market that is rapidly evolving and becoming increasingly technology-driven.

Mid-sized and emerging players, including WuXi AppTec, Berkeley Lights, Advanced Instruments, and Creative Biolabs, are steadily gaining market visibility by delivering highly specialized and niche solutions such as modular workcells, closed-system bioreactors, and AI-enabled process monitoring platforms. These companies are strengthening their market presence through strategic collaborations with biopharmaceutical companies and contract development and manufacturing organizations (CDMOs), benefiting from the growing industry demand for scalable and GMP-compliant automated platforms. Although their current market share remains comparatively smaller, their innovation-focused strategies and differentiated product offerings position them well for strong growth in the coming years.

From a geographical perspective, North America continues to lead the market, supported by early adoption of advanced manufacturing technologies, the strong presence of major industry players, and sustained investments in biomanufacturing infrastructure. Europe follows closely, with countries such as Germany, the UK, and France contributing significantly due to favorable regulatory frameworks, active government support, and well-established biotechnology ecosystems. Meanwhile, the Asia-Pacific and Middle East regions are experiencing gradual market expansion, driven by increasing healthcare investments, a growing number of clinical trials, and the establishment of regional CDMOs that are increasingly adopting automated processing systems.

Overall, the market share landscape is divided between large, established corporations that generate substantial revenues from global operations and smaller, emerging innovators that are building relevance through specialized technologies and targeted solutions. Strategic mergers, acquisitions, and partnerships are actively reshaping the competitive environment, enabling key players to broaden their product portfolios, strengthen their technological capabilities, and better address the evolving needs of cell and gene therapy manufacturers across both clinical and commercial development stages. Innovation and industry consolidation are expected to continue influencing market share dynamics over the forecast period.

Key Players

• Miltenyi Biotec

• Lonza

• Fresenius Kabi AG

• Danaher Corporation

• BioSpherix, LLC

• Terumo Corporation

• Sartorius AG

• ThermoGenesis Holdings, Inc.

• CELLARES

• Thermo Fisher Scientific Inc.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The automated and closed cell therapy processing systems market is experiencing strong momentum due to the growing demand for efficient, scalable, and contamination-free manufacturing solutions. Increasing adoption of regenerative medicine and cell and gene therapies is driving the need for advanced automation technologies. Integration of software, robotics, and closed-system platforms is improving process consistency, safety, and regulatory compliance.